Effects of endocrine disruptors on genes associated with 17beta-estradiol metabolism and excretion

• Published in: Steroids Vol. 73; no. 12; p. 1242
• Main Authors: Hanet, Nathalie, Lancon, Allan, Delmas, Dominique, Jannin, Brigitte, Chagnon, Marie-Christine, Cherkaoui-Malki, Moustapha, Latruffe, Norbert, Artur, Yves, Heydel, Jean-Marie
• Format: Journal Article
• Language: English
• Published: United States 01.11.2008
• Subjects: Base Sequence; Blotting, Western; Cell Line; DNA Primers; Endocrine Disruptors - pharmacology; Estradiol - metabolism; Gene Expression Regulation - drug effects; Humans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics
• ISSN: 0039-128X
• DOI: 10.1016/j.steroids.2008.06.005

In order to provide a global analysis of the effects of endocrine disruptors on the hormone cellular bioavailability, we combined 17beta-estradiol (E2) cellular flow studies with real-time PCR and Western blot expression measurements of genes involved in the hormone metabolism and excretion. Three endocrine disruptors commonly found in food were chosen for this study, which was conducted in the estrogen receptor (ER) negative hepatoblastoma HepG2 cell line: bisphenol A (BPA), genistein (GEN) and resveratrol (RES). We showed that 24 h after a single dose treatment with genistein, resveratrol or bisphenol A, the expression of ATP-binding cassette transporters (the multidrug resistance or MDR, and the multidrug resistance associated proteins or MRP) uridine diphosphate-glucuronosyltransferases (UGT) and/or sulfotransferases (ST) involved in 17beta-estradiol elimination process were significantly modulated and that 17beta-estradiol cellular flow was modified. Resveratrol induced MDR1 and MRP3 expressions, bisphenol A induced MRP2 and MRP3 expressions, and both enhanced 17beta-estradiol efflux. Genistein, on the other hand, inhibited ST1E1 and UGT1A1 expressions, and led to 17beta-estradiol cellular retention. Thus, we demonstrate that bisphenol A, genistein and resveratrol modulate 17beta-estradiol cellular bioavailability in HepG2 and that these modulations most probably involve regulations of 17beta-estradiol phase II and III metabolism proteins. Up to now, the estrogenicity of environmental estrogenic pollutants has been based on the property of these compounds to bind to ERs. Our results obtained with ER negative cells provide strong evidence for the existence of ER-independent pathways leading to endocrine disruption.